Close Menu

Ambry

The deal will join the AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.

Ambry will provide genetic testing in NorthShore’s Genomic Health Initiative in hopes of moving precision medicine into clinical practice.

The company expects the deal will help it launch an immunostaining technology, expand into US pharma services, and establish itself as a genetic testing leader in Japan.

Konica said that the deal represents its first step toward building a presence in the precision medicine field, with an eye toward Japan and then Europe.

Pages